| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121, 2018 | 3741 | 2018 |
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ... New England Journal of Medicine 366 (2), 109-119, 2012 | 3085 | 2012 |
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation M Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, ... New England Journal of Medicine 377 (6), 523-533, 2017 | 2936 | 2017 |
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised … L Gianni, T Pienkowski, YH Im, L Roman, LM Tseng, MC Liu, A Lluch, ... The lancet oncology 13 (1), 25-32, 2012 | 2646 | 2012 |
| Palbociclib and letrozole in advanced breast cancer RS Finn, M Martin, HS Rugo, S Jones, SA Im, K Gelmon, N Harbeck, ... New England journal of medicine 375 (20), 1925-1936, 2016 | 2550 | 2016 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous … M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ... The Lancet Oncology 17 (4), 425-439, 2016 | 1740 | 2016 |
| Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Masuda, SJ Lee, S Ohtani, YH Im, ES Lee, I Yokota, K Kuroi, SA Im, ... New England Journal of Medicine 376 (22), 2147-2159, 2017 | 1577 | 2017 |
| Trastuzumab deruxtecan in previously treated HER2-positive breast cancer S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ... New England Journal of Medicine 382 (7), 610-621, 2020 | 1522 | 2020 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1208 | 2020 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1124 | 2022 |
| Overall survival with palbociclib and fulvestrant in advanced breast cancer NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ... New England journal of medicine 379 (20), 1926-1936, 2018 | 1034 | 2018 |
| Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ... Journal of clinical oncology 23 (11), 2493-2501, 2005 | 989 | 2005 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 944 | 2018 |
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ... The lancet oncology 19 (7), 904-915, 2018 | 892 | 2018 |
| Overall survival with ribociclib plus endocrine therapy in breast cancer SA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ... New England journal of medicine 381 (4), 307-316, 2019 | 891 | 2019 |
| 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre … L Gianni, T Pienkowski, YH Im, LM Tseng, MC Liu, A Lluch, ... The lancet oncology 17 (6), 791-800, 2016 | 875 | 2016 |
| OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2 … ME Robson, N Tung, P Conte, SA Im, E Senkus, B Xu, N Masuda, ... Annals of Oncology 30 (4), 558-566, 2019 | 656 | 2019 |
| Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer J Cortés, SB Kim, WP Chung, SA Im, YH Park, R Hegg, MH Kim, ... New England Journal of Medicine 386 (12), 1143-1154, 2022 | 649 | 2022 |
| Overall survival with ribociclib plus fulvestrant in advanced breast cancer DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... New england Journal of medicine 382 (6), 514-524, 2020 | 646 | 2020 |
| Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ... The lancet oncology 13 (12), 1225-1233, 2012 | 641 | 2012 |
Yung-Jue BangProfessorVerified email at boconsulting.io
